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Abstract 
Introduction: A comparative animal study of the efficacy of intermittent short-course administration of lyophilised single-, three-, and 
live multistrain probiotic on obesity. 
Methods: We included 70 rats divided into seven groups (n = 10 in each). Rats of group I were intact. Newborn rats of groups II–VII were 
injected with monosodium glutamate (MSG) (4 mg/g). Rats of group II (MSG-obesity group) were untreated. The group III-V received 
lyophilised monoprobiotics B. animalis VKL, B. animalis VKB, and L. casei IMVB-7280, respectively. Group VI received the mix of these 
three probiotic strains. Group VII was treated with multiprobiotic “Symbiter”, which contains 14 live probiotic strains (Lactobacillus, Bifi-
dobacterium, Propionibacterium, Acetobacter genera). 
Results: Neonatal treatment with MSG caused stunted growth, which is why, despite the lack of weight gain dynamics and absence of 
significant food consumption rate and body weight changes at day 120, we noted the development of obesity in all MSG-obesity rats 
and in up to 20–70% after probiotic administration. Supplementation of probiotic composition, with preference to live strains, led to 
a significantly lower prevalence of obesity, and reduction of VAT weight and serum lipid levels as compared to single-strain probiotic. In 
our comparative single-strain analysis a trend towards more pronounced hypolipidaemic effect and VAT weight reduction was observed 
for lyophilised L. casei IMVB-7280 as compared to B. animalis VKL and VKB strains. 
Conclusions: Multistrain formed mutualistic interactions in mixtures and therefore able to share with different metabolites, affect diffe-
rent receptors and produced various of biologically active compounds which synergistic overall effect greater than the sum of the single 
effects. (Endokrynol Pol 2017; 68 (6): 659–667)
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Streszczenie
Wstęp: Badania porównawcze na zwierzętach oceniające skuteczność w zapobieganiu otyłości podawania w krótkotrwałych cyklach 
liofilizowanych preparatów zawierających jeden, trzy lub więcej żywych szczepów probiotycznych. 
Materiał i metody: Do badania włączono 70 szczurów podzielonych na 7 grup (n = 10 w każdej grupie). Szczury w grupie I nie zostały 
poddane żadnej interwencji. Noworodkom szczurów w grupach II–VII wstrzyknięto glutaminian jednosodowy (monosodium glutamate, 
MSG) (4 mg/g). U szczurów z grupy II (z otyłością indukowaną MSG) niż stosowano żadnego leczenia. Szczury w grupach III–V otrzy-
mywały liofilizowane probiotyki, odpowiednio B. animalis VKL, B. animalis VKB i L. casei IMVB-7280. Grupie VI podawano mieszankę 
tych trzech szczepów. W grupie VII stosowano wieloskładnikowy preparat probiotyczny „Symbiter” zawierający 14 żywych szczepów 
(Lactobacillus, Bifidobacterium, Propionibacterium, Acetobacter). 
Wyniki: Podanie szczurzym noworodkom MSG spowodowało zahamowanie wzrostu, jednak mimo wolniejszego przyrostu masy ciała 
i braku istotnych zmian wielkości spożycia karmy i masy ciała po 120 dniach zaobserwowano rozwój otyłości u wszystkich szczurów 
z otyłością indukowaną MSG i u 20–70% zwierząt otrzymujących probiotyki. Podawanie kompozycji probiotyków, szczególnie żywych 
szczepów, prowadzi do istotnego zmniejszenia częstości występowania otyłości, ilości tkanki tłuszczowej trzewnej i stężania lipidów 
w surowicy w porównaniu ze stosowaniem preparatów jednoszczepowych. W analizie porównawczej preparatów jednoskładniko-
wych stwierdzono tendencję w kierunku silniejszego działania hipolipemicznego i większej redukcji tkanki tłuszczowej trzewnej 
w przypadku liofilizowanego szczepu L. casei IMVB-7280 niż szczepów B. animalis VKL i VKB. 
Wnioski: W preparatach wieloszczepowych powstają wzajemne interakcje umożliwiające wymianę różnych metabolitów, wpływ na różne 
receptory i produkcję różnych biologicznie czynnych cząsteczek, których ogólny efekt synergistyczny jest większy niż suma efektów 
jednostkowych. (Endokrynol Pol 2017; 68 (6): 659–667)
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Introduction
Overweight and obesity are defined as abnormal or 
excessive fat accumulation that may impair health. The 
worldwide prevalence of obesity more than doubled 
between 1980 and 2014, and for today the World Health 
Organisation has declared obesity as a global epidemic 
and has taken it under control. In 2014, more than 1.9 
billion adults older than 18 years (39%) are overweight. 
Overall, about 13% or 600 million of the adult popula-
tion (11% of men and 15% of women) are obese [1]. 
The most frequent cause that leads to obesity de-
velopment is an imbalance between energy intake and 
energy expenditure. In this complex process genetic 
susceptibility, and environmental and lifestyle factors 
are involved. Current research efforts have focused on 
host and environmental factors that may affect energy 
balance [2].
Recent studies have revealed a whole new insight 
into obesity, suggesting a link between intestinal mi-
crobes and weight gain [3]. Authors suggest that gut 
microbiota are involved in the control of body weight, 
energy homeostasis, and inflammation, and thus play 
a role in the pathophysiology of obesity [4]. Dietary vari-
ation and caloric intake induce changes in gut micro-
biome composition, selectively promoting the growth 
of certain microbes [5]. These gut microbes thrive and 
impact the host metabolism by affecting inflammation 
and fat storage [6, 7]. 
Prebiotics and probiotics are of interest because 
they have been shown to alter the composition of gut 
microbiota and to affect food intake, appetite, body 
weight, and composition as well as metabolic functions 
through gastrointestinal pathways and modulation 
of the gut bacterial community [8]. At present, the 
question of the probiotics’ influence on lipid metabo-
lism and obesity is actively debated in the scientific 
literature [9–11]. 
The importance of microbiota modification in the 
conditions of obesity has been confirmed by numerous 
studies of the probiotic interventions. The analysis of 
more than 20 articles from 2013 to July 2014 by Cani et 
al. showed that at least 15 different strains of Lactoba-
cillus and two strains of Bifidobacterium do not equally 
influence on body weight, fat mass, glucose metabolism, 
inflammatory markers, plasma and hepatic lipids, and 
plasma cholesterol levels [12]. 
In our previous work, we showed the development 
of non-alcoholic fatty liver disease (NAFLD) under 
conditions of the severe visceral obesity induced by 
neonatal administration of monosodium glutamate 
(MSG) [13]. Thus, the obtained results confirmed the 
validity of the usage of MSG for NAFLD development. 
Moreover, short-term courses of multiprobiotic cocktails 
lead to significant reduction of hepatic steatosis, total 
lipids, and triglycerides content in the liver, as well as 
preventing the development of NAFLD in animals, 
as compared to MSG-obesity littermates. More pro-
nounced changes were observed after administration 
of probiotic mixture preferably containing alive strains 
as compared to lyophilised cocktails; our data also sug-
gest failure of NAFLD prevention with monoprobiotic 
strains [14]. Based on this suggestion, it was interesting 
to compare the influence of the of mono-strain and pro-
biotic compositions in lyophilised or live conditions in 
the prevention and treatment of obesity. Therefore, the 
aim of the current work was a comparative animal study 
of the efficacy of intermittent short-course administra-
tion of lyophilised single-, three-, and live multistrain 
probiotic on the development of obesity.
Materials and methods 
Ethics Statement
This study was carried out in strict accordance with 
the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes 
of Health and the general ethical principles of animal 
experiments, approved by the First National Congress 
on Bioethics, Ukraine (September 2001). The protocol 
was approved by the Committee on the Ethics of 
Animal Experiments of Taras Shevchenko National 
University of Kyiv (Protocol number: 6/2015). The rats 
were kept in collective cages in controlled conditions 
of temperature (22 ± 3°C), light (12-h light/dark cycle), 
and relative humidity (60 ± 5%). 
Study design
We included 70 newborn Wistar male rats, divided 
into seven groups of 10 animals (Fig. 1). Group 1 
intact rats were administered neonatally with hyper-
tonic saline (1.25 mg/g body weight per day, control 
group) subcutaneously (s.c.) on the 2nd, 4th, 6th, 8th, and 
10th postnatal days. All newborn rats except controls 
were injected with monosodium glutamate — MSG 
(4 mg/g body weight per day) on the 2–10th days of 
life, to induced obesity [15]. Six pups per mother 
were standardised to ensure better lactation. After 
the weaning, one-month-old MSG-treated animals 
were randomly divided into six groups, treated and 
untreated with probiotics. From weaning (four weeks) 
to 120 days of age, rats had free access to standard 
rodent chow (PurinaW) and water during the entire 
experimental period.
Group II (MSG-obesity) received 2.5 ml/kg of wa-
ter (intragastrically). Group III-V received lyophilized 
monoprobiotics B. animalis VKL, B. animalis VKB, L. casei 
IMVB-7280 at a dose of 50 mg/kg (5 × 109 CFU/kg), 
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respectively. Group VI received 2.5 ml/kg of an aqueous 
solution of a mixture of the three probiotic strains (2:1:1 
Lactobacillus casei IMVB-7280, Bifidobacterium animalis 
VKL, Bifidobacterium animalis VKB) at a dose of 50 mg/kg 
(5 × 109 CFU/kg) (g) (intragastrically). Group VII was 
treated with multiprobiotic “Symbiter” containing 
a biomass of 14 live probiotic strains (Lactobacillus + 
Lactococcus [6 × 1010 CFU/g], Bifidobacterium [1 × 1010/g], 
Propionibacterium [3 × 1010/g], Acetobacter [1 × 106/g]) 
at a dose of 140 mg/kg (1.4 × 1010 CFU/kg). The mul-
tiprobiotic “Symbiter” was supplied by Scientific and 
Production Company “O.D. Prolisok”. The treatment 
with probiotics was started at the age of one month and 
had been performed for three months in 2 two-week 
courses (one course per month). All parameters were 
measured in four-month-old rats.
Anthropometric measurements and obesity  
parameter assessment
During four months, in all groups, the changes in 
body weight and food intake were analysed. In adult 
age, rats from the three experimental groups (n = 70) 
were weighed and killed by cervical dislocation under 
urethane anaesthesia. We dissected and weighed vis-
ceral adipose tissue (VAT) (epididymal, perirenal, and 
omental fat).
For each animal at month four of life (120 days) 
we determined the existence of obesity using the Lee 
index. It was calculated as follows: the cube root of 
body weight (g)/naso-anal length (cm) [16, 17]. Rats 
presenting values higher than 0.300 were classified as 
obese, and equal to or less than 0.300 as normal [18].
Sample collection and blood biochemistry analysis
Rats of all groups were fasted for approximately 12 
hours prior to sacrifice. Blood was collected into a micro-
centrifuge tube containing a mixture of NaF and EDTA 
in a 2:1 (w/w) ratio, centrifuged for 10 min at 1000 g, fol-
lowed by selection of serum. Cholesterol, triglycerides, 
high-density lipoprotein (HDL), low-density lipopro-
tein (LDL), and very-low-density lipoproteins (VLDL) 
in serum were determined by standard biochemical 
methods. Lipid extraction from liver was performed 
according to Folch et al. [19].
Statistical analysis
Statistical analysis was performed using SPSS-20 soft-
ware. All data in this study were expressed as mean ± 
standard error (M ± SEM) or percentage. Data distri-
bution was analysed using the Kolmogorov-Smirnov 
normality test. Continuous variables with parametric 
distribution were analysed using Analysis of Vari-
ance (ANOVA), and if the results were significant, 
a post-hoc Turkey’s test was performed. For data 
with non-parametric distribution, Kruskall-Wallis and 
post-hoc Tukey’s test were conducted for multiple 
comparisons. For comparisons of categorical variables 
we conducted a χ2 test. The difference between groups 
was defined to be statistically significant when a p-value 
was less than 0.05.
Results
Figure 2A presents weight gain dynamics of the dif-
ferent experimental groups. Initial assessments of 
body weight were performed before administration 
of probiotic started at 30-days of life. In this time point 
the lowest body weight was observed in intact rats, 
which was significant as compared to all other groups. 
At day 60 and after one month of probiotic administra-
tion there were no significant changes in body weight 
between intact and both lyophilised (VI) and live (VII) 
poliprobiotic groups. However, we observed signifi-
cantly lower weight in these three groups as compared 
to MSG-obesity and after single-strain (III–V) probiotic 
correction, respectively. Later, in terms of 90 and 120 
days, body weight flattened, and at the end of experi-
ment the weight of all rats did not differ significantly 
(Fig. 3A). Also, we did not find significant changes in 
food consumption rates between all groups at each 
time point (Fig. 2B).
Neonatal treatment with MSG caused stunted 
growth, which is one of the main characteristic 
features of this experimental obesity model. In our 
study animals of group II–VII were characterised by 
significantly smaller naso-anal length compared to 
intact rats (Fig 3B). That is why, despite the lack of 
Figure 1. The design of the study. Three arrows with the 
corresponding signs demonstrate experimental groups of animals 
and the manipulation within these groups
Rycina 1. Projekt badania. Trzy strzałki z odpowiednimi 
oznaczeniami odpowiadają grupom eksperymentalnym zwierząt 
oraz działaniom prowadzonym w obrębie tych grup
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Figure 2. Weight dynamics and food consumption rate in experimental animals
Rycina 2. Zmiany masy ciała a spożycie karmy w grupie obserwowanych zwierząt
Figure 3. Anthropometric parameters in 4-month-old rats in the condition of MSG-induced obesity and after probiotic administration 
(A — body weight; B — naso-anal length; C — Lee index; D — visceral adipose tissue weight). Data are presented as the M ± SEM. 
One-way ANOVA with post hoc Tukeys test for multiple comparisons were performed for data analysis. a, b, cValues at the same row with 
different superscript letters shows significant differences in p < 0.05
Rycina 3. Parametry antropometryczne 4-miesięcznych szczurów z otyłością indukowaną MSG i po stosowaniu probiotyków (A — 
masa ciała, B — długość nosowo-odbytnicza, C — wskaźnik Lee, D — masa tkanki tłuszczowej trzewnej)
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weight gain dynamics and absence of significant body 
weight changes at day 120, we noted 100% develop-
ment of obesity in MSG-obesity rats and up to 70% 
after probiotic administration, which was significantly 
higher compared to intact animals (p < 0.001), where 
obesity was not found (Fig. 4). On the other hand, 
it should be noted that administration of probiotic 
cocktails led to a significantly lower prevalence of 
obesity as compared to single-strain probiotic groups 
(III–V). The maximum preventive effect was described 
for the live multiprobiotic Symbiter group (VII), in 
which development of obesity was seen in only 20% 
of rats (Fig. 4).
The obtained results were fully confirmed by the 
Lee index, in which values more than 0.300 were used 
to confirm obesity in rats. The average value of the Lee 
index in MSG-obesity rats was 0.343 ± 0.006, which 
was significantly higher as compared to intact animals 
(0.276 ± 0.008, p < 0.001) (Fig. 3C). The preventive 
effect of probiotics was confirmed by significantly 
lower Lee index in all probiotic groups as compared 
to MSG-obesity. On the other hand, correction with 
probiotics did not provoke significant recovery of the 
Lee index to the intact rats’ value (Fig. 3C). Although 
we did not notice significant probiotics intergroup 
differences according to Lee index value, the most 
important decreases were observed for both polipro-
biotic groups (group VI — 0.298 ± 0.005 and group 
VII — 0.298 ± 0.004).
We found that neonatal MSG administration led to 
the development of severe abdominal obesity. The total 
VAT weight in rats from MSG-obesity group was 16.93 
± 0.43 g that in 6.2 times higher as compared to intact 
rats (p < 0,001) (Fig 3D).
The administration of probiotics led to significant 
reduction of VAT accumulation for all interventional 
groups as compared to the MSG-obesity group (p < 
0.001). Differences between these groups were insig-
nificant; nevertheless, according to viability and strain 
dependence of probiotic composition, certain preven-
tive features were noted. The lowest total VAT weight 
was measured after correction with alive multiprobiotic 
“Symbiter” (group VII). Only for this probiotic composi-
tion we did not observed significant difference on VAT 
weight as compared to intact rats (5.79 ± 0.75 g vs. 2.72 
± 0.2 g, p = 0.112) (Fig. 3D, 5).
Changes of total VAT weight in monocomponent 
probiotic groups (III-V) detected a strain-specific 
trend to a more pronounced visceral fat accumulation 
reduction with probiotic based on lyophilised L. casei 
IMVB-7280 as compared to B. animalis VKL and VKB 
strains (Fig. 3D).
It is well known that obesity is characterised by lipid 
metabolism changes. The administration of probiotics 
carried a significant strain-dependent effect on lipid 
metabolism in experimental animals (Fig. 6). The most 
pronounced lipid-lowering effects were observed for 
the live poliprobiotic group (group VII). The use of 
“Symbiter” led to a significant reduction of serum TG 
and total cholesterol on 46.4% (p < 0.001) and 26.1% 
(p < 0.001), respectively, as compared to MSG-obesity 
(Fig. 6A, C). Moreover, lipid concentration restored 
almost to the level of intact rats, which was accompa-
nied by a lack of significant difference between these 
experimental groups.
Interestingly, that single-strain L. casei IMVB-7280 
probiotic led substantially to the same as in group VII: 
significant reduction of TG level on 44.1% (p < 0.001) 
as compared to MSG-obesity (Fig. 6A). As well as the 
Symbiter group, a statistically significant difference 
between monocomponent group and intact rats was 
absent (p = 0.100). However, as compared to group 
VII, use of L. casei IMVB-7280 did not demonstrate the 
same total cholesterol lowering effect (Fig. 6C).
Poliprobiotic lyophilised (group VI) and single- 
-strain probiotics containing B. animalis VKL and VKB 
(Group III–IV) also had a slight hypolipidaemic effect, 
which resulted in significant reduction of total choles-
terol and TG as compared MSG-obesity, but this effect 
did not reach the level of intact animals (Fig. 6A, C).
After treatment with probiotics the serum level of 
LDL was the same and on average significantly de-
creased by 20–30% as compared to the MSG-obesity 
group (Fig. 6D). Differences between all interventional 
groups (III–VII) and intact rats were insignificant. 
Figure 4. Prevalence of obesity (% rate) in 4-month-old rats 
in the condition of MSG-induced obesity and after probiotic 
administration
Rycina 4. Częstość występowania otyłości (%) u 4-miesięcznych 
szczurów z otyłością indukowanej MSG i po stosowaniu 
probiotyków
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The HDL level did not change significantly after 
single-strain probiotics (group III–V) as compared to 
MSG-obesity. For poliprobiotic groups, regardless of 
strain activity, we noted a tendency to increase HDL le-
vels by 20–25% (Fig. 6B). However, despite the moderate 
effectiveness, biochemical parameters of lipid metabo-
lism were not normalised to the level of the intact rats.
Discussion
Preclinical evidence supporting the “anti-obesity” ef-
fects of probiotics comes mainly from studies on single-
strain probiotics belonging to the Lactobacillus and 
Bifidobacterium genera, which are common inhabitants 
of the human intestinal ecosystem. Also, most of the cur-
rent research aimed at providing weight management 
through probiotic administration thus far has been 
conducted in animal models of diet-induced obesity.
Several studies carried out on high-fat diet (HFD) 
or high-sucrose diet (HSD) induced obesity in mice 
when administered or supplemented for more than 
eight weeks with one or a number of Lactobacillus strains 
such as Lactobacillus plantarum LG42 [20], L. gasseri 
BNR17 [21], L. gasseri SBT2055 [22], Lactobacillus curvatus 
HY7601, and L. plantarum KY1032 [23] accompanied by 
significant reduction in weight gain and VAT mass and 
a relatively lowered level of serum and liver lipid con-
tents, parallel to reduced expression of lipogenic genes 
(ACC1, FAS, SREBP-1, LXR-α), whereas it increased the 
hepatic PPAR-α, UCP2, and CPT-1 mRNA levels, which 
upregulate the expression of enzymes involved in fatty 
acid oxidation. Therefore, data obtained on the genetic- 
-determined models of obesity are still ambiguous. On 
the one hand, dietary supplementation with Lactobacil-
lus gasseri NT significantly decreased VAT weight and 
TG in the liver in KK-A(y) mice on a high-fat diet via 
reduction of lipid digestion/absorption [24]. On the 
other hand, Hamad et al., when assessing the effect of 
probiotic L. gasseri SBT2055 supplementation, observed 
a decrease in mesenteric fat weight, adipocyte sizes, and 
both serum and liver cholesterol contents only in lean 
rats as compared to obese Zucker rats. However, an 
increased excretion of faecal fatty acids and total neu-
tral faecal sterols in both rat strains was observed [25].
Strain-dependent anti-obesity effect of different Lac-
tobacillus containing probiotics were well exemplified in 
Fak and Backhed’s study. In a mouse model of obesity 
(Apoe-/- mice) three strains of L. reuteri: ATCC PTA 4659 
(ATCC), DSM 17938 (DSM), and L6798, were tested 
when supplemented to HFD for eight weeks, for the 
anti-obesity, anti-inflammatory, and anti-atherogenic 
effects. They found that only L. reuteri ATCC gained 
significantly less body weight than the control mice, 
whereas the L6798 mice gained significantly more. 
L. reuteri strain ATCC PTA 4659 partly prevented diet-in-
duced obesity, via induction of liver expression of Cpt1; 
Figure 5. Original photos of visceral adipose tissue mass in 4-month-old rats in the condition of MSG-induced obesity and after 
administration of alive probiotic composition (group VII)
Rycina 5. Oryginalne fotografie przedstawiające tkankę tłuszczową trzewną u 4-miesięcznych szczurów z otyłością indukowaną MSG 
i po stosowaniu kompozycji żywych szczepów probiotycznych (grupa VII)
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however, no anti-inflammatory or anti-atherosclerotic 
effect was achieved irrespective of the treatment [26]. 
It is well known that diet is one of the most influ-
ential factors for altering microbiota composition, so in 
contrast to the majority of other studies, which used 
high-fat diets for the study of the effects of probiotics, 
we used MSG-induced obesity models in rats, which 
were characterised by severe visceral obesity and stunt-
ed growth. Also, it is worth noting that different effects 
have been observed depending on the strain used, and 
the action of the probiotics is tightly connected with 
the properties and viability of each strain. Therefore, as 
compared to similar studies with single-strain fashion, 
we first compared the influence of the of lyophilised 
mono-strain and probiotic compositions in lyophilised 
or live conditions in the development of obesity.
It was established that intermittent short-term 
courses of probiotic administration started from 30 days 
of life had different amounts and strain-dependent 
anti-obesity effects. Neonatal treatment with MSG 
caused stunted growth, which is why, despite the lack 
of weight gain dynamics and absence of significant food 
consumption rate and body weight changes at day 120, 
we noted 100% development of obesity in MSG-obesity 
rats and up to 20–70% after probiotic administration. 
Supplementation of probiotic composition, with 
preference to live strains, led to a significantly lower 
prevalence of obesity, and reduction of VAT weight and 
serum lipid levels as compared to single-strain probiotic 
groups (III–V).
At least partly, similarly to our design, a study that 
focused on comparative analysis, but in single-strain 
Figure 6. Serum lipids levels in 4-month-old rats in the condition of MSG-induced obesity and after probiotic administration (A — 
triglycerides; B — HDL-cholesterol; C — total cholesterol; D — LDL-cholesterol). Data are presented as the M ± SEM. One-way 
ANOVA with post hoc Tukeys test for multiple comparisons was performed for data analysis. a, b, cValues in the same row with different 
superscript letters show significant differences in p < 0.05
Rycina 6. Stężenie lipidów w surowicy 4-miesięcznych szczurów z otyłością indukowaną MSG i po stosowaniu probiotyków (A — 
triglicerydy; B — cholesterol frakcji HDL; C — cholesterol całkowity; D — cholesterol frakcji LDL)
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fashion, were reported. It has recently been reported 
that 12-week dietary supplementation with either Lac-
tobacillus paracasei CNCM I-4270, Lactobacillus rhamnosus 
I-3690, or Bifidobacterium animalis subsp. lactis I-2494 sig-
nificantly attenuated HFD-induced weight gain despite 
no reductions in food intake in mice [27]. Similar results 
have been obtained in studies where Bifidobacterium spp. 
(B. pseudocatenulatum SPM 1204, B. longum SPM 1205, and 
B. longum SPM 1207 [28], B. adolescentis [29], B. breve B-3 
[30], B. lactis 420 [31]) was added to a HFD in rats. In the 
study by Yin et al., rats with HFD-induced obesity were 
treated with four strains of Bifidobacteria (L66-5, L75-4, 
M13-4, and FS31-12). Namely, B L66-5 blunted the diet-
induced increase in body weight, while B M13-4 further 
enhanced it. Whereas no differences in relative body fat 
content were found among treatments. Therefore, all four 
strains were associated with reductions in serum and 
liver TG, and significantly alleviated lipid deposition in 
liver. Only Bifidobacterium L66-5 and Bifidobacterium FS31-
12 decreased cholesterol liver content significantly [32]. 
In our comparative single-strain probiotic analysis 
a trend towards more pronounced hypolipidaemic ef-
fect and VAT weight reduction was observed for lyoph-
ilised L. casei IMVB-7280 as compared to B. animalis VKL 
and VKB strains. Furthermore, L. casei IMVB-7280 led 
substantially to the same as for the live multiprobiotic 
group (VII): a significant reduction of TG level.
The number of microbial species found in the gut is 
huge, and the interactions among them and with the 
host cells need to be further explained so that probiotic 
strains can be used with a rationale [33]. Preclinical 
studies have been conducted that used different bacte-
rial strains, animal models, and lengths of administra-
tion. Nearly all studies have shown some anti-obesity 
property of probiotics. However, despite a large body 
of evidence supporting the anti-obesity and favourable 
metabolic effects of probiotics, it should be borne in 
mind that these effects may vary dramatically, depend-
ing both on the bacterial strain and on the host [2].
Conclusions
Administration from childhood of probiotic composi-
tion, with a preference to live strains, led to a signifi-
cantly lower prevalence of obesity, and reduction of VAT 
weight and serum lipid levels as compared to single-
strain probiotic groups (III–V). It may be related to more 
pronounced viability of live strains and their preven-
tion of bacterial translocation. Multistrain or multispe-
cies formed mutualistic interactions in mixtures and 
therefore were able to share with different metabolites, 
affect different receptors, and produced various biologi-
cally active compounds which synergistic overall effect 
greater than the sum of the single effects.
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